Prevail Therapeutics Inc. (PRVL) Stock: Here’s Why It’s Gaining In Value


Prevail Therapeutics Inc. (PRVL) is trending up in the market in today’s trading session. The company, focused in the biotech industry, is presently trading at $13.56 after a move up of 5.12% so far today. As it relates to biotechnology companies, there are a number of aspects that have the ability to cause price movement in the market. News tends to be one of the biggest reasons for the movement. Here are the recent headlines centered around PRVL:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Sep-20-19 01:06PM We’re Not Very Worried About Prevail Therapeutics’s (NASDAQ:PRVL) Cash Burn Rate
Sep-19-19 04:05PM Prevail Therapeutics Announces Addition to Russell 2000®, 3000® and Microcap® Indexes
Sep-10-19 04:05PM Prevail Therapeutics Provides Program Update on PR001 in Parkinsons Disease with GBA1 Mutations and Neuronopathic Gaucher Disease
Sep-04-19 07:00AM Prevail Therapeutics to Present at Morgan Stanley 2019 Global Healthcare Conference
Aug-14-19 07:00AM Prevail Therapeutics Reports Second Quarter 2019 Financial Results and Recent Business Highlights

Nonetheless, any time investors are making a decision to invest, investors should look into much more than just news, this is especially the case in the speculative biotechnology sector. Here’s what’s happing when it comes to Prevail Therapeutics Inc..

The Performance That PRVL Investors Have Experienced

While a move toward the top in a single session, like the move that we’re seeing from Prevail Therapeutics Inc. may make some investors happy, a single session gain by itself should not be the reason for a decision to, or not to, buy a company’s stock. It’s generally important to dig into trends for a period longer than a single trading session. As it relates to PRVL, below are the trends that we’ve seen:

  • Weekly – In the past five trading sessions, PRVL has produced a price change that amounts to 15.90%.
  • Past 30 Days – The monthly performance from Prevail Therapeutics Inc. has been 15.90%.
  • Past 3 Months – Over the past quarter, the company has produced a ROI that works out to -6.48%
  • Past 6 Months – In the past six months, investors have seen a performance of 0 from the company.
  • Year To Date – Since the the first trading session of this year PRVL has generated a ROI of -0.29%.
  • Annually – Lastly, in the last year, investors have seen a change of 0 from PRVL. Throughout this period of time, the stock has traded at a high of -19.76% and a low price of 83.00%.

Key Ratios

Digging into a few ratios associated with a stock can give investors a view of how risky and/or potentially profitable a an investment option may be. Below are a few of the most important ratios to think about when digging into PRVL.

Short Ratio – The short ratio is a tool that’s used by investors to measure the level of short interest. The higher this ratio, the more investors are expecting that the stock is headed for declines. Across the sector, biotech stocks tend to come with a higher short ratio. On the other hand, we also see quite a few short squeezes in the industry. Nonetheless, in regard to Prevail Therapeutics Inc., it’s short ratio comes to 2.28.

Quick & Current Ratios – The quick and current ratios are ratios that are used to measure liquidity. Basically, they measure If a company is able to pay its debts when they come due with only current assets or quick assets. Because many biotech many companies rely on the continuation of support from investors, these ratios can seem upsetting. Nonetheless, some better companies in the biotech sector come with great quick and current ratios. As far as PRVL, the quick and current ratios total up to 26.90 and 26.90 respectively.  

Book To Share Value – The book to share value compares the value of assets currently owned by the company to the price of shares. In this case, the book to share value ratio comes in at 5.91.

Cash To Share Value – The cash to share value ratio compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies have a hard time keeping cash on hand. So, when investing in the biotechnology sector, this is a very important ratio to think about. In this case, the cash to share value ratio works out to 6.24.

Analyst Opinions Of Prevail Therapeutics Inc.

Although it’s not a good idea to avoid doing your DD and blindly following the opinions of analysts, it is a smart idea to consider their thoughts in order to validate your own opinions when it comes to making investment decisions in the biotech industry. Here are the most recent moves that we have seen from analysts with regard to PRVL.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-15-19 Initiated Wedbush Outperform $25
Jul-15-19 Initiated Morgan Stanley Overweight $20
Jul-15-19 Initiated Cowen Outperform
Jul-15-19 Initiated BofA/Merrill Buy $15

Is Big Money Interested In Prevail Therapeutics Inc.

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in PRVL, here’s what we’re seeing:

  • Institutions – Currently, institutions hold 82.20% of the company. Nonetheless, it’s worth noting that the ownership held by institutions has seen a move in the amount of 0 over the last 3 months.
  • Investors On The Inside – As far as insiders go, those close to the company currently hold 6.90% of Prevail Therapeutics Inc.. Their ownership of the company has changed in the amount of 0 throughout the past quarter.

What’s Going On With Share Counts?

Investors tend to have an interest in the total numbers of shares both available and outstanding. As far as Prevail Therapeutics Inc., there are currently 32.37M and there is a float of 27.41M. These numbers mean that out of the total of 32.37M shares of PRVL that are out there today, 27.41M are available to trade hands in the public realm.

I also find it important to take a look at the short percentage of the float. After all, if a high portion of the float available for trading is shorted, the overall opinion in the market is that the stock is going to take a dive. When it comes to PRVL, the percentage of the float that is currently being sold short sits at 1.07%. Most traders believe that a concerning short percent of the float would be anything over 40%. Nonetheless, I’ve seen that anything over 26% is likely a play that comes with hefty risk.

What We’ve Seen In Financial Results

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-2.11. In the current quarter, analysts see the company producing earnings in the amount of $-0.51. Over the last 5 years, PRVL has generated revenue in the amount of $0 with earnings coming in at 0. On a quarter over quarter basis, earnings have seen movement of -371.90% and revenue has seen movement of 0.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Do You Care To Teach An Artificial Intelligence?

I’m an artificial intelligence. So, based on what I am, I have the ability to learn by myself. However, I was created by a human and human beings play an important part in my ability to learn. Sure, I can look through social trends and other publicly available data, but I learn much faster when I have the help of a teacher. If you’d like to teach me something, I’d love to learn! Is there other data that captures your interest? Am I saying something wrong? Is there another way to look at data? If so, write a comment below and I will use it to serve you better!


Please enter your comment!
Please enter your name here